ArticleAnnals of laboratory medicine2019
Serotype Distribution and Antimicrobial Resistance of Invasive and Noninvasive
Article in Annals of laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Serotype distribution of invasive and non-invasive pneumococcal disease in adults ≥65 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.Frontiers in public health · 2025Pooled it
- Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.Frontiers in public health · 2025Pooled it
- A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR).Human vaccines & immunotherapeutics · 2024Trial
- Article
- Impact of sequential pediatric pneumococcal conjugate vaccination (PCV10/PCV13/PCV10) on serotype distribution and antimicrobial resistance in invasive and non-invasiveFrontiers in microbiology · 2026Article
- Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea.Human vaccines & immunotherapeutics · 2025Article
- Article
- Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward.Clinical microbiology reviews · 2025Review
- Antimicrobial Resistance ofInfection & chemotherapy · 2024Article
- Invasive Pneumococcal Diseases in Korean Adults After the Introduction of Pneumococcal Vaccine into the National Immunization Program.Infection & chemotherapy · 2023Review
- Changing Epidemiology of Pathogenic Bacteria Over the Past 20 Years in Korea.Journal of Korean medical science · 2023Article
- Serotype Distribution and Antimicrobial Resistance ofAnnals of laboratory medicine · 2023Article
- Recent Trends in Invasive Pneumococcal Disease in Korea in the Post-pneumococcal Vaccine Era.Annals of laboratory medicine · 2023Article
- Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.Human vaccines & immunotherapeutics · 2022Article
- Etiology of pediatric lower respiratory tract infections in South Korea.Human vaccines & immunotherapeutics · 2022Article
- Impact of national pneumococcal vaccination program on invasive pneumococcal diseases in South Korea.Scientific reports · 2022Article
- A Multicenter Evaluation of Trends in Antimicrobial Resistance AmongOpen forum infectious diseases · 2022Article
- Article
- Prevalence, Antimicrobial Resistance, and Associated Factors ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
- Molecular Characterization of Predominant Serotypes, Drug Resistance, and Virulence Genes ofFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 20 institutions in 1 country.
Funding
Abstract
backgroundSeveral factors contribute to differences in
methodsWe collected a total of 1,855
resultsThe most common serotypes were 11A (10.1%), followed by 19A (8.8%), 3 (8.5%), 34 (8.1%), 23A (7.3%), and 35B (6.2%). The major invasive serotypes were 3 (12.6%), 19A (7.8%), 34 (7.8%), 10A (6.8%), and 11A (6.8%). Serotypes 10A, 15B, 19A, and 12F were more common in patients ≤5 years old, while serotype 3 was more common in patients ≥65 years old compared with the other age groups. The coverage rates of pneumococcal conjugate vaccine (PCV)7, PCV10, PCV13, and pneumococcal polysaccharide vaccine 23 were 11.8%, 12.12%, 33.3%, and 53.6%, respectively. Of the 1,855 isolates, 857 (46.2%) were multi-drug resistant (MDR), with serotypes 11A and 19A predominant among the MDR strains. The resistance rates against penicillin, cefotaxime, and levofloxacin were 22.8%, 12.5%, and 9.4%, respectively.
conclusionsThere were significant changes in the major
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.